Search

Researchers at Abou Bekr Belkaid University conducted a study on the potential interaction between levothyroxine sodium and thyme (Thymus vulgaris) in thyroid drugs. The study focused on a case report of a 52-year-old woman who experienced palpitations after consuming T. vulgaris tea while on levothyroxine therapy for hypothyroidism. The researchers concluded that there is a probable interaction between levothyroxine sodium and thyme, highlighting the importance of caution when using herbal remedies alongside conventional treatments for thyroid disorders. The study was published in the Journal of Pharmacy & Pharmacognosy Research and can be accessed for further information. [Extracted from the article]

Recent research from the University of Illinois highlights the potential impact of GLP-1 RA therapy on thyroid stimulating hormone levels in post-thyroidectomy patients. A case study revealed suppressed TSH levels in a patient after starting subcutaneous semaglutide, leading to a dose reduction of levothyroxine. The study suggests the need for closer monitoring of patients on GLP-1 RA therapy and further research in this area to better understand the effects on thyroid function. [Extracted from the article]

Researchers at Mustansiriyah University conducted a study in Karbala City to estimate the prevalence of primary hypothyroidism and its clinical manifestations among patients receiving levothyroxine therapy. The study found that levothyroxine treatment improved symptoms such as sluggish speech, constipation, lack of appetite, cold sensitivity, weight gain, and weariness. The research concluded that there was no observed correlation between the dosage of levothyroxine and the manifestation of signs and symptoms. The study was published in the Al-Mustansiriyah Journal of Pharmaceutical Sciences in 2024. [Extracted from the article]

A study from Jiangsu, China, explored the link between subclinical hypothyroidism (SCH) and adverse pregnancy outcomes, as well as the effects of levothyroxine (LT4) therapy on maternal and infant prognosis. The research found that SCH during pregnancy increased the risk of hypertensive disease, fetal growth restriction, premature delivery, and fetal death. However, LT4 replacement therapy was shown to improve outcomes for both mothers and infants, regardless of thyroid peroxidase antibody (TPOAb) status. The study involved 635 pregnant women with SCH and 1876 women with normal thyroid function as a control group. [Extracted from the article]

The article discusses a clinical trial, NCT06660823, focusing on the role of levothyroxine supplementation in aiding delayed recovery post cardiac surgery. Hypothyroidism has been linked to various cardiovascular and respiratory complications, affecting heart function and recovery. The study aims to investigate the effects of oral levothyroxine supplementation on patients experiencing delayed recovery after cardiac surgery, with a focus on improving physical fitness and heart function. The trial is set to enroll adult patients aged 45-70 years in Egypt, with a primary completion date of May 31, 2025. [Extracted from the article]

A recent study conducted at Semmelweis University analyzed factors influencing the dose of levothyroxine treatment in patients with hypothyroidism of different etiologies. The study found that patients with autoimmune hypothyroidism required significantly lower doses of levothyroxine compared to those with post-surgery hypothyroidism. Factors such as age, body weight, BMI, and time since diagnosis were identified as significant predictors of levothyroxine requirement in patients with autoimmune hypothyroidism. The research highlights the importance of considering the underlying cause of hypothyroidism when determining levothyroxine replacement therapy. [Extracted from the article]

A recent study conducted at Zuyderland Medical Center focused on patient experiences and preferences regarding the recommended fasting administration of levothyroxine (LT4) for thyroid treatment. The research found that while 97.3% of patients received instructions to fast before taking LT4, only 30% adhered to this recommendation. Many patients expressed a preference for non-fasting LT4 ingestion due to the burden of postponing breakfast, leading to irregular intake and even medication omission. The study suggests further research into alternative non-fasting administration methods to improve adherence and patient satisfaction. [Extracted from the article]

A recent study from Cardiff University delves into the complexities of hypothyroidism, a common condition globally that affects various body systems and can present with a range of symptoms. The research highlights the importance of individualized reference intervals for thyroid function tests and discusses the standard treatment of levothyroxine therapy. The study also addresses ongoing debates surrounding treatment thresholds and strategies for managing hypothyroidism, providing valuable insights for future research in this field. [Extracted from the article]

Researchers from a Cancer Hospital in Faisalabad, Pakistan, conducted a study on the rapid absorption of levothyroxine to assess nonadherence to treatment in six patients with persistent hypothyroidism. The study found that a 2-hour levothyroxine absorption test could be a more convenient method to differentiate nonadherence from malabsorption. The research concluded that scheduling patients for testing may result in improved adherence to levothyroxine therapy. The study was published in the European Journal of Medical Case Reports in 2024. [Extracted from the article]

A recent study conducted at the University of Miami focused on the combined use of propylthiouracil (PTU) and levothyroxine (LT4) in treating monocarboxylate transporter 8 (MCT8) deficiency in 12 male patients. The research aimed to identify optimal therapeutic dosages and evaluate treatment safety and outcomes. Results showed that the combined treatment effectively normalized serum thyroid hormone levels in patients with MCT8 deficiency, emphasizing the importance of individualized dose adjustments for personalized treatment plans. The study was funded by the National Institutes of Health (NIH) and the Esformes Thyroid Research Fund, and has been peer-reviewed for publication in Thyroid. [Extracted from the article]

A study conducted at Bashkir State Medical University in Ufa, Russia, compared the effects of low-iodine diet and methimazole-induced hypothyroidism on oxidative metabolism in the liver of rats. The research found that the low-iodine diet model led to more significant inhibition of thyroid function compared to the methimazole-induced hypothyroidism model. The results suggest that conflicting data on oxidative metabolism in hypothyroidism may be due to different approaches used to model thyroid dysfunction. For more information, the study was published in the Biomedical and Pharmacology Journal. [Extracted from the article]

A recent study conducted by researchers at the Central Arkansas Veterans Healthcare System aimed to determine the frequency and determinants of levothyroxine therapy initiation for veterans with subclinical hypothyroidism (SCH). The study found that 27.5% of veterans with SCH were treated with levothyroxine. Factors associated with higher odds of treatment included being White and having a higher thyrotropin level. The study suggests potential disparities and the influence of SCH severity on treatment decision-making. Further research is needed to better understand the reasons behind these findings. [Extracted from the article]

A study conducted at Shanxi Bethune Hospital aimed to assess the impact of extrathyroidal autoimmune diseases (ADs) on the clinical characteristics and efficacy of iodine-131 (131I) therapy in patients with differentiated thyroid cancer (DTC). The study found that while extrathyroidal ADs may enhance the detection of DTC among elderly women, they have no impact on the clinical characteristics of thyroid cancer or the efficacy of 131I therapy. The presence of ADs may require higher dosages of levothyroxine in patients with DTC. The study suggests that the presence of ADs does not need to be considered when designing treatment plans for patients with DTC. [Extracted from the article]

A study conducted by researchers at Charles University in the Czech Republic has found that levothyroxine, a drug used to treat thyroid conditions, can have varying bioavailability depending on the formulation and brand. The researchers used a non-targeted analytical approach to examine different levothyroxine formulations and discovered unexpected compounds, including degradation products and undeclared phospholipids. This study suggests that current quality control mechanisms may not fully capture the complexity of pharmaceutical formulations. The findings highlight the importance of further investigation into the safety and efficacy of thyroid drugs. [Extracted from the article]

A recent study conducted in Bangladesh aimed to fill the knowledge gap regarding primary hypothyroidism in the country. The study included 2,641 adult patients with primary hypothyroidism who had been on levothyroxine (L-T4) replacement therapy for at least 1 year. The study found that only 26.8% of patients had high adherence to L-T4, and nearly half of the patients did not have optimal L-T4 replacement. Factors associated with uncontrolled hypothyroidism included a vegetarian diet, smokeless tobacco use, disease duration over 5 years, consumption of iron or calcium supplements within 4 hours of L-T4 intake, and low or medium adherence to L-T4. The researchers concluded that physicians should address the barriers to reaching the therapeutic goal for these patients. [Extracted from the article]

A new report discusses research findings on female infertility, specifically the relationship between subclinical hypothyroidism (SCH) and perinatal outcomes in singleton pregnancies resulting from assisted reproduction technology (ART). The study found that women with SCH had an increased risk of preterm birth before 34 weeks. However, the use of levothyroxine therapy was found to be a significant protective factor against preterm birth. The researchers suggest that universal screening for thyroid function and appropriate hormone therapy in pregnant women may help reduce perinatal risks, including preterm birth. [Extracted from the article]

A study conducted at the All India Institute of Medical Sciences (AIIMS) aimed to understand the clinical manifestations and outcomes of antithyroid drug therapy (ATD) among patients with Graves' disease in central India. The study found that the prevalence of Graves ophthalmopathy was low, and the rates of remission in response to ATD were also low. Factors such as the grade of goiter, T3 and fT4 levels at diagnosis, and peak carbimazole dose were found to predict non-remission. This research provides valuable insights into the efficacy of ATD therapy for Graves' disease in this specific population. [Extracted from the article]

A study conducted by researchers at Dalian University of Technology in Liaoning, China, has investigated the effects and mechanisms of chemical permeation enhancement (CPE) on the transdermal permeation of levothyroxine sodium (L-T4) patches. The researchers found that the combination of oleic acid (OA) and Azone (NZ) resulted in the best transdermal permeation effect for L-T4. They also discovered that OA improves drug release by increasing the flowability of the pressure-sensitive adhesive (PSA) matrix, and both OA and NZ facilitate L-T4 permeation through the hair follicle pathway. The study concluded that these patches showed a remarkable therapeutic effect on hypothyroidism without causing skin irritation or cytotoxicity. [Extracted from the article]

A recent study conducted by the National Medicines Institute in Warsaw, Poland, explores the challenges and dissatisfaction experienced by patients undergoing levothyroxine replacement therapy for hypothyroidism. The research suggests that the varying response to levothyroxine may be influenced by a complex interplay of individual, environmental, genetic, and epigenetic factors, with immunological disturbances playing a significant role. The study emphasizes the need for a personalized approach to treatment strategies for hypothyroidism. This information provides valuable insights for individuals seeking to understand the causes of difficulties in achieving target thyrotropin levels and persistent symptoms despite hormone replacement therapy. [Extracted from the article]

A recent study conducted at Tsinghua University in Beijing, China, explored the effectiveness of levothyroxine sodium tablets (L-T4) in treating severe complications of hypothyroidism, specifically kidney injury, muscle injury, and lipid metabolism disorders. The study focused on a 52-year-old woman with Hashimoto thyroiditis (HT), a common cause of hypothyroidism. After two months of L-T4 treatment, the patient experienced improvements in kidney function, muscle health, and lipid profile. The study suggests that L-T4 therapy can partially reverse the complications associated with HT and alleviate related symptoms. [Extracted from the article]

A recent study conducted at the National Research Centre in Egypt has found that co-administering xylo-oligosaccharides (XOS) produced by immobilized Aspergillus terreus xylanase with the drug carbimazole can help mitigate its adverse effects on the adrenal glands. The study showed that XOS not only accelerates the regeneration of adrenal gland cells but also decreases oxidative stress caused by obesity. The immobilized enzyme used in the study demonstrated superior thermal stability and sustained its activity even after multiple cycles and storage. This research provides a potential solution for reducing the harmful effects of carbimazole on the adrenal glands. [Extracted from the article]

A recent study conducted at Maria Curie Sklodowska University in Lublin, Poland compared the catalytic activity of two antithyroid agents, carbimazole and methimazole, on the electroreduction of zinc. The researchers used electrochemical methods to analyze the kinetics and mechanism of zinc electroreduction on a mercury electrode in the presence of these drugs. Molecular dynamics simulations were also performed to understand the effect of the drugs on the hydration sphere of Zn2+ ions. The study found that both carbimazole and methimazole exhibited catalytic abilities, with carbimazole being more effective at lower concentrations and methimazole being more effective at higher concentrations. The presence of both drugs and an increase in the concentration of the supporting electrolyte enhanced the rate of electroreduction. [Extracted from the article]

New research conducted at the University of Porto in Portugal has focused on the therapeutic applications of potassium iodide, particularly its role in shielding the thyroid during radiation emergencies. The ongoing conflict between Ukraine and Russia, as well as concerns about nuclear weapons, have led to a surge in demand for potassium iodide across Europe. The research reviews the current knowledge on the pharmacology, physiology, adverse effects, and protective role of potassium iodide in reducing the risk of thyroid cancer during radiation emergencies. It concludes that while potassium iodide protects the thyroid from radioiodine, it does not affect the absorption of other radioactive materials or defend against external radiation exposure. [Extracted from the article]

Researchers from the University of Sao Paulo in Brazil have conducted a study on the effectiveness of photodynamic inactivation (PDI) against Pseudomonas aeruginosa biofilm. P. aeruginosa is a gram-negative bacterium that is responsible for 7% of hospital-acquired infections and has high mortality rates. The study found that PDI, which involves the use of a photosensitizer and light to produce reactive oxygen species, was effective in reducing the biofilm. The addition of potassium iodide (KI) to the photosensitizer solution further increased the effectiveness of the treatment, resulting in complete eradication of the biofilm. The use of KI in association with a photosensitizer called methylene blue (MB) showed the most promising results. This research provides valuable insights into potential strategies for combating P. aeruginosa infections. [Extracted from the article]

A study conducted at Mayo Clinic Arizona has provided new insights into hypersensitivity reactions caused by the drug methimazole (MMI) in patients with Graves disease. The research found that MMI can commonly result in skin allergies, which may lead to discontinuation of therapy. However, the study presented a case of successful treatment using a novel, individualized desensitization protocol that resulted in tolerance of MMI and improvement in thyroid indices. The study suggests that a slower desensitization protocol can be considered for delayed hypersensitivity reactions to MMI, offering an alternative for patients who wish to avoid definitive therapy. [Extracted from the article]

A new report from Shanghai University in China discusses the influence of a combination treatment of propranolol and methimazole on patients with hyperthyroidism. The study compared two groups of patients, one treated with methimazole alone and the other with propranolol plus methimazole. The results showed that the combination treatment was more effective in improving heart rate, thyroid hormone levels, hepatic function, and quality of life, with a lower incidence of adverse reactions. The study also identified AST (aspartate aminotransferase) as an independent risk factor for ineffective treatment. Overall, the findings suggest that propranolol plus methimazole is an effective treatment option for hyperthyroidism. [Extracted from the article]

A recent article in Drug Week discusses new findings on thyroid drugs. The research highlights that thyroid hormones are typically given orally for substitution therapy in patients with hypothyroidism. However, there are some indications for intravenous use of thyroid hormones, such as when oral medications cannot be absorbed properly or in cases of altered consciousness or shock. The article also mentions the use of intravenous levothyroxine in treating myxedema coma and its potential protective effect on the heart in brain-dead organ donors. Overall, the research provides insights into the various applications of thyroid drugs. [Extracted from the article]

A study conducted at Ganzhou People's Hospital focused on the factors that influence postoperative TSH suppression therapy in patients with papillary thyroid carcinoma (PTC). The study included 268 patients who underwent surgery for PTC and received postoperative TSH suppression therapy. The researchers compared various clinical data, laboratory test indicators, medication dosage, and follow-up frequency between patients who achieved the target TSH level and those who did not. The study found that adjusting the dose of levothyroxine sodium in a timely manner during follow-up visits is crucial for optimal thyroid function in PTC patients post-surgery. [Extracted from the article]

A case report from researchers in Guarda, Portugal highlights the rare occurrence of methimazole-induced hepatitis in a 12-year-old boy with hyperthyroidism. Methimazole is commonly used to treat hyperthyroidism due to its low risk of adverse reactions. The patient experienced signs and symptoms of thyrotoxicosis but did not show clinical findings related to liver damage. After discontinuing methimazole treatment and receiving ablative therapy, the patient showed excellent clinical and analytical improvement. The researchers emphasize the importance of monitoring liver enzymes and thyroid function to promptly recognize and prevent unfavorable outcomes. [Extracted from the article]

A study conducted by Shanghai Jiao Tong University School of Medicine in China explored the case of an elderly male patient with hyperthyroidism who experienced intolerance to oral medication and radioiodine treatment. As a result, the patient was treated with methimazole cream, which led to significant improvement in symptoms and a decline in thyroid function indicators. The study deviated from conventional medication selection and provided clinical reference for the use of topical formulations. The research highlights the importance of considering individual patient needs and exploring alternative treatment options. [Extracted from the article]

A recent study conducted by researchers at the Alexandria Faculty of Medicine focused on the use of levothyroxine therapy in patients with autoimmune hypothyroidism. The study aimed to determine the optimal weight-based doses of levothyroxine needed to achieve target thyrotropin levels in different degrees of hypothyroidism. The study found that the weight-based dose of levothyroxine varied depending on the severity of hypothyroidism, with higher doses required for more severe cases. Additionally, age and body weight subcategories were found to be important factors in determining the appropriate dosage. This study provides valuable insights for clinicians in managing autoimmune hypothyroidism. [Extracted from the article]

A recent study conducted at the Third Affiliated Hospital of Zhengzhou University evaluated the efficacy of different doses of levothyroxine therapy in pregnant women with high-normal thyroid stimulating hormone (TSH) levels and positive thyroid peroxidase antibodies (TPOAb) during the first half of pregnancy. The study found that supplementation with 50 g of levothyroxine was more effective in improving blood lipid status and gastrointestinal symptoms, reducing the incidence of small intestinal bacterial overgrowth (SIBO) and premature rupture of membranes, and mitigating the risk of spontaneous abortion. The research suggests that pregnant women with these conditions may benefit from this treatment approach. [Extracted from the article]

A recent report from Mayo Clinic discusses the findings of a study on hypothyroidism. The study aimed to determine the frequency of persistent or new symptoms in patients with hypothyroidism after starting levothyroxine (LT4) therapy. The study included 356 patients, the majority of whom were female, white, and obese, with an average age of 59.5 years. The results showed that approximately 1 in every 4 patients with hypothyroidism receiving LT4 therapy and achieving normal thyroid stimulating hormone (TSH) levels experience persistent or new hypothyroid symptoms. The cause of these symptoms remains unclear, highlighting the need for further research and effective management strategies. [Extracted from the article]

A recent report from the University of Science and Technology Beijing explores the use of amoxicillin and potassium iodide as a hybrid corrosion inhibitor for mild steel in a hydrochloric acid (HCl) environment. The study found that the combination of these two substances resulted in a synergistic and highly efficient green inhibitor, with an inhibition efficiency of up to 97.7%. The hybrid inhibitor was effective in inhibiting both the cathodic and anodic reactions, and further analysis confirmed the formation of synergistic adsorption films. This research opens up possibilities for the development of new environmentally friendly corrosion inhibitors. [Extracted from the article]

This document provides information about a clinical trial, NCT06272721, that aims to investigate the impact of hypothyroidism in pregnancy on the neuropsychological development of children. The study will focus on cognitive and neuropsychological outcomes, specifically in the areas of learning and language. It will involve 31 women diagnosed with hypothyroidism and a control group of 21 women without hypothyroidism. The study will analyze pregnancy outcomes, complications in mothers, and cognitive-neuropsychological outcomes in children using the Griffiths Mental Development Scales II. The study is not yet recruiting participants and is expected to be completed by May 31, 2024. [Extracted from the article]

A research report from Madhya Pradesh, India, discusses the efficacy and safety of 5 days a week levothyroxine versus daily replacement therapy in patients with hypothyroidism. The study found that the 5 days a week regimen was noninferior to the daily regimen and increased compliance and satisfaction levels in patients. The research concludes that the 5 days a week levothyroxine replacement regimen can be conveniently prescribed for treating hypothyroidism. [Extracted from the article]

A study conducted at the Government Medical College in Kerala, India, aimed to determine the efficacy of a levothyroxine dosage regimen based on serum thyrotropin (TSH) levels for primary hypothyroidism. The study found that categorizing patients based on TSH levels led to euthyroidism in approximately four out of five patients. Factors such as pre-treatment TSH levels, serum thyroxine levels, and body weight were found to correlate with the levothyroxine dosage required for adequate replacement. The study provides valuable insights into individualized initial levothyroxine dosage for primary hypothyroidism. [Extracted from the article]

A study conducted at Akron Children's Hospital in Ohio investigated the use of intravenous levothyroxine in unstable brain-dead heart donors. The researchers randomly assigned potential heart donors to receive either levothyroxine or a saline placebo. The study found that there was no significant difference in the number of hearts transplanted between the two groups. However, there were more cases of severe hypertension and tachycardia in the levothyroxine group. Overall, the study concluded that intravenous levothyroxine infusion did not result in more hearts being transplanted than saline infusion. [Extracted from the article]

A recent study by Merck Healthcare KGaA highlights the importance of managing hypothyroidism during pregnancy. The research emphasizes that overt hypothyroidism can lead to adverse pregnancy outcomes, including miscarriage, and recommends thyroid hormone replacement therapy with levothyroxine (LT4) to reduce these risks. The study also suggests that subclinical hypothyroidism may decrease the chance of a successful pregnancy outcome, and intervention may be necessary for certain patients. However, the study notes that hypothyroidism in pregnancy is often overlooked or not appropriately treated, indicating a need for further research to identify barriers to optimal thyroid care during this critical time. [Extracted from the article]

A recent study conducted at Shahid Chamran University Ahvaz in Iran explored the anti-thyroid properties of methimazole and its derivatives. The researchers investigated the iodine adsorption capacity and anti-thyroid activity of six methimazole-based bidentate ligands. The compounds showed a remarkable ability to adsorb iodine, making them potential candidates for new anti-thyroid drugs. The study also suggested that these compounds could be used in the design of novel materials for iodine uptake purposes. The research was supported by Shahid Chamran University of Ahvaz and has been peer-reviewed. [Extracted from the article]

New research conducted at the University of Michigan focuses on the quality and stability of levothyroxine tablets, a commonly prescribed thyroid medication. The study examines the impact of excipients, or inactive ingredients, on the potency and stability of the tablets. The researchers found that the choice of excipients can affect the quality of the medication, and low potency has been a common reason for product recalls. The study also evaluates the stability of different brands of levothyroxine tablets under various conditions. The findings suggest that two brands remained stable at 6 months under ambient conditions, but some distinguishing data were observed under stress conditions. Overall, the number of levothyroxine tablet recalls has decreased over the years. This research provides valuable insights into the quality control of levothyroxine tablets and highlights the importance of excipients in maintaining the stability of the medication. [Extracted from the article]

A study conducted at Guangdong Pharmaceutical University in China explored the use of 3D printing technology to improve the quality and clinical efficacy of subdivided levothyroxine sodium tablets. The study compared the quality and effectiveness of tablets subdivided using 3D printing technology with those subdivided manually. The results showed that the 3D-printed tablets met the required quality standards, while the manually subdivided tablets did not. Additionally, the study found that the 3D-printed tablets had a positive impact on thyroid hormone levels and weight gain in premature infants. The researchers concluded that 3D printing technology is a superior method for subdividing drugs and improving their efficacy. [Extracted from the article]

A recent study conducted by researchers at the University of Helsinki and Helsinki University Hospital in Finland explored the impact of levothyroxine treatment on urinary luteinizing hormone (LH) measurements in pediatric patients with thyroid disease. The study found that urinary LH concentrations correlated significantly with serum LH levels in patients not receiving levothyroxine treatment, but no significant correlation was observed in patients receiving levothyroxine. The researchers concluded that urinary LH measurements can be used to assess pubertal development in patients with thyroid pathology, as long as the patient is not on levothyroxine treatment. However, urinary thyroid-stimulating hormone (TSH) measurements cannot replace invasive serum TSH measurements, at least in patients with normal serum TSH levels. Further research is needed to determine the utility of urinary TSH measurements in patients with elevated serum TSH levels. [Extracted from the article]

A recent study conducted at Chi Mei Medical Center in Tainan, Taiwan, explored the effects of extra-low dose levothyroxine supplementation on pregnancy outcomes in women with subclinical hypothyroidism (SCH) undergoing in vitro fertilization (IVF) and embryo transfer. The study found that supplementing SCH women with an extra-low dose of levothyroxine (25 mcg/day) produced comparable obstetrical and neonatal outcomes to euthyroid pregnant women. The researchers suggest that extra-low-dose levothyroxine may be a safe and effective alternative for SCH pregnant women who cannot tolerate the standard dose. The study included 589 women, with 167 of them being clinically pregnant after IVF treatment. The average age of the participants was 35 years old. The study did not find any significant differences in age, body mass index, anti-mullerian hormone levels, types of embryo transfer, number of embryos transferred, or embryo stage during transfer between the two groups. The live birth rate, miscarriage rate, preterm birth rate, and small for gestational age rate in women with SCH supplemented with extra-low dose levothyroxine were non-inferior to euthyroid patients. The study was published in the Taiwanese Journal of Obstetrics & Gynecology. [Extracted from the article]

A study conducted by researchers at King Saud University in Saudi Arabia investigated the use of beryllium oxide (BeO) fullerene-like particles for drug delivery of methimazole (MET). The researchers used density functional theory (DFT) calculations to optimize the molecular models and analyze their structural and electronic features. They found that the zinc-enhanced ZnBeO particles were more suitable for the formation of MZnBeO complexes, which could potentially improve the drug delivery process. The study provides insights into the potential use of fullerenes in drug delivery systems. [Extracted from the article]

A recent study conducted by researchers at the University of Florida examined the concomitant use of levothyroxine (LT4) and interacting medications in ambulatory care visits in the United States. LT4 is a commonly prescribed medication and can be impacted by drug-drug interactions, particularly with over-the-counter drugs. The study found that 24.4% of visits involving patients with a LT4 prescription also involved the use of interacting drugs, with proton pump inhibitors being the most common. Factors such as age, gender, and the time period of the visit were associated with increased odds of concomitant interacting drug use. The researchers suggest that further research is needed to understand the consequences of this concomitant use. [Extracted from the article]

A recent study conducted at Rhode Island Hospital focused on the management of hypothermia and hyponatremia in a case of myxedema coma. The study examined the case of a 69-year-old Caucasian male who presented to the hospital after a fall. The patient exhibited symptoms of lethargy and hypothermia, with a rectal temperature of 84.9 °F. Active rewarming was initiated, which led to hypotensive episodes. The patient was treated with glucocorticoids and levothyroxine, and his hyponatremia improved with fluid restriction and levothyroxine replacement. The study concluded that active rewarming should be avoided in cases of myxedema, and hyponatremia in myxedema coma can be corrected with fluid restriction and levothyroxine replacement. [Extracted from the article]

Researchers from Shiraz University of Medical Sciences in Iran have conducted a study on the use of paclitaxel, a potent anticancer agent, for drug delivery to cancer cells. The researchers conjugated paclitaxel with a water-soluble and biocompatible polymer called dextran to enhance its solubility. They also conjugated levothyroxine, a thyroid drug, to dextran to provide targeted delivery. The study found that the drug conjugates showed higher cytotoxicity on certain cell lines compared to the free drugs, and pre-treatment with levothyroxine decreased cytotoxicity on specific cell lines. The researchers concluded that the levothyroxine targeted dextran conjugate could be an effective strategy for delivering paclitaxel to different cell lines. [Extracted from the article]